Top news
Evidence mounts for need to study Pfizer's Paxlovid for long COVID - researchers say
By Julie Steenhuysen
Doctors investigating why some report rebound in COVID-19 symptoms after Paxlovid
By Arielle Mitropoulos
Pfizer Says Patients Who Relapse After Covid Pill Can Take More
By Robert Langreth, Riley Griffin & Madison Muller
All coverage
Paxlovid prescriptions to treat Covid increased tenfold in U.S. since late February, Pfizer says
By Spencer Kimball
Pfizer confident in COVID pill Paxlovid's $22B sales potential
By Fraiser Kansteiner
Pfizer keeps COVID sales forecast unchanged as pandemic curbs ease
By Michael Erman & Manas Mishra
FDA warns Paxlovid as COVID treatment option
By Zoey Becker